Vioxx ERISA Plaintiffs Seek To Add Vytorin To Mix

Law360, New York (April 17, 2008, 12:00 AM EDT) -- The plaintiffs in a shareholder lawsuit over Merck & Co. Inc.'s shelved Vioxx painkiller have asked a court for permission to amend their complaint to include allegations that the company covered up evidence that its cholesterol drug Vytorin was less effective than advertised.

As in the ongoing Vioxx litigation, the proposed amendment to the complaint, filed Thursday in the U.S. District Court for the District of New Jersey, alleges that Merck's misconduct in hiding the results of clinical trials violated the Employee Retirement Income Security Act...
To view the full article, register now.